172P Phase I study of JTX-8064, a LILRB2 (ILT4) inhibitor, as monotherapy and combination with pimivalimab (pimi), a PD-1 inhibitor (PD-1i), in patients (pts) with advanced solid tumors

K Papadopoulos,P Lorusso,J Powderly,C Tasillo Kadra,N Mota,R.E Sanborn,G Giaccone,V.T-L Ma,G Gibney,X Xiao,T George,D.G.K Teoh,B Umiker,E Trehu,D Kilari,K Yalamanchili,S Ghamande,J Brown,T Li,N Lakhani

doi:10.1016/j.iotech.2022.100284

172P Phase I study of JTX-8064, a LILRB2 (ILT4) inhibitor, as monotherapy and combination with pimivalimab (pimi), a PD-1 inhibitor (PD-1i), in patients (pts) with advanced solid tumors

K Papadopoulos, P Lorusso + Show 18 more

Open Access

https://doi.org/10.1016/j.iotech.2022.100284

Copy DOI

Journal: Immuno-Oncology and Technology	Publication Date: Dec 1, 2022
Citations: 1	License type: cc-by-nc-nd

Affiliation: South Texas Accelerated Research Therapeutics

#Leukocyte Immunoglobulin Like Receptor B2 #Advanced Solid Tumors + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

JTX-8064, a highly selective and potent IgG4 inhibitor of myeloid-specific Leukocyte Immunoglobulin Like Receptor B2 (LILRB2), leads to macrophage reprogramming from an immunosuppressive to an immune activated state, resulting in T cell activation. INNATE (NCT04669899) is a phase (P) 1/2 dose escalation/expansion study of two investigational agents, JTX-8064 monotherapy (mono) and combination (combo) with pimi. P1 data defining Recommended P2 Dose (RP2D) are presented.

Full Text